Patients with previous unprovoked venous thromboembolism (VTE) and persistent antiphospholipid antibodies fulfil the criteria for antiphospholipid syndrome (APS), and are usually offered long-term treatment with vitamin K antagonists (VKA) because of the risk of recurrent events [1].
Patients with previous unprovoked venous thromboembolism (VTE) and persistent antiphospholipid antibodies fulfil the criteria for antiphospholipid syndrome (APS), and are usually offered long-term treatment with vitamin K antagonists (VKA) because of the risk of recurrent events [1] .
On the contrary, VKAs require regular monitoring and maintaining the international normalized ratio (INR) within the target therapeutic range can be challenging for some. Furthermore, unique to APS, VKA monitoring can be complicated by the variable responsiveness of reagents used in the INR test to lupus anticoagulants, leading to instability of anticoagulation, and an inaccurate reflection of the true level of anticoagulation [2] .
The worldwide approval of rivaroxaban, and more latterly, other novel oral anticoagulants (NOAs), for the secondary prevention of VTE may represent a major advance for the treatment of patients with APS and previous VTE. NOAs potentially would result in improved quality of life in patients with APS who generally require an indefinite period of anticoagulation because unlike warfarin, NOAs do not require monitoring and have no major food or alcohol interactions and few reported drug interactions.
To assess rivaroxaban in comparison with VKAs in the secondary prevention of VTE in APS, the UK-based rivaroxaban in APS (RAPS trial) is currently ongoing [3] . RAPS is a prospective randomized trial of warfarin versus rivaroxaban in patients with previous VTE and APS, with or without systemic lupus erythematosus, being maintained at a target INR of 2.5 (range 2.0-3.0).
In this letter, we report our preliminary experience with rivaroxaban use in patients with APS with previous VTE and poor anticoagulation control with VKA. They were started on rivaroxaban prior to the start of the RAPS study or failed to qualify for RAPS (e.g. less than 18 years' old).
Secondly, we aimed to evaluate the diagnostic accuracy of lupus anticoagulant testing in patients with APS while on rivaroxaban, comparing results with their previous tests, when they were not receiving anticoagulation.
Thirty-five patients, fulfilling the current APS criteria [4] and attending our Thrombosis Centre, were included [24 female, 11 male, median age 47 (range 17-75), median disease duration 9 (1-18) years, median age at onset of disease 33 (15-69) years]. Twenty-four had previous deep vein thrombosis and 11 had both deep vein thrombosis and pulmonary embolism. They all were receiving a VKA and had a target INR of 2-3; those requiring a higher target INR were excluded. The included patients' time in therapeutic range was 65% or lower. Indication for switching from VKA to rivaroxaban 20 mg od for secondary prevention of VTE were erratic INR control [median 13 (9-23) INR tests within the last 6 months] in 29 patients and INR constantly sub-therapeutic range in six patients.
Patients were switched from VKA to rivaroxaban 20 mg daily and the patients were followed for a median of 10 months (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Women in the rivaroxaban arm were advised not to become pregnant.
No further VTE, major bleeding events or serious sideeffects were seen except in two women in whom worsening of menorrhagia was seen.
Extreme caution should be applied in interpreting our preliminary observations. However, we consider that NOAs might represent a promising alternative in APS patients with previous venous thromboembolism. Results from the RAPS study will be available next year and will address this issue.
Recently, Schaefer et al. [5] reported the failure of dabigatran and rivaroxaban for secondary thromboprophylaxis in three patients with APS. Our results disagree with their experience, probably because of the different subset of patients in the two studies. Two of three patients reported by Schaefer et al. [5] had previous arterial thrombotic events (cerebral infarction and radial artery thrombosis). Previous arterial thrombosis was an exclusion criterion in our study, as we use an INR target of 3-4 in these patients when compared with patients with previous VTE. Therefore, until the equivalent dosing of NOAs to an INR of 3-4 is known, we will not be using NOAs for secondary thromboprophylaxis in patients with previous arterial event. Patient 3 was reported as having cirrhosis and oesophageal varices. It is arguable to attribute the portal vein thrombosis to the failure of rivaroxaban only, as several additional factors might have contributed. Firstly, portal vein thrombosis is a common complication of liver cirrhosis [6] . Secondly, the subacute/chronic features shown at the venogram might call into questioning the timing of the event. Lastly, rivaroxaban was stopped for 6 days before admission.
It is debatable whether the detection of lupus anticoagulants may be affected by rivaroxaban. We compared testing for lupus anticoagulants in patients on rivaroxaban with their previous tests, when they were not receiving anticoagulation. Diagnostic accuracy for lupus anticoagulants testing during rivaroxaban treatment is shown in Table 1 . Taipan snake venom time had the best specificity and positive predictive value when compared to dilute activated partial thromboplastin time and dilute Russell's viper venom time (dRVVT). Our results support previous observations suggesting that Taipan/Ecarin time is poorly affected by the presence of rivaroxaban [7] . The observation that dRVVT is the test most affected by rivaroxaban [8] is not surprising, as Russell's Viper Venom and rivaroxaban share the same target (factor Xa). However, in our study, false-positive results were seen with all types of lupus anticoagulant testing, suggesting they cannot be used diagnostically while patients receive rivaroxaban, although this needs confirming in studies designed specifically to address this question.
In summary, our study suggests the use of rivaroxaban therapy for secondary thromboprophylaxis for APS patients with previous VTE looks promising, but that lupus anticoagulant testing in patients receiving rivaroxaban seems unreliable. In the interim, our observations suggest that rivaroxaban may be considered cautiously as an alternative anticoagulant in APS patients with previous VTE, who require a target INR of 2-3, but have poor anticoagulant control with VKA.
We have recently read with great interest the article by Sensoy et al. describing the management of obstructive prosthetic tricuspid valve thrombosis in two patients [1] . Although patients were successfully treated with slow (6 h), single infusion of low-dose (50 mg) tissue plasminogen activator (tPA), we want to address some points that merit more attention.
Prosthetic heart valve thrombosis (PHVT) is a life-threatening complication whose management remains controversial. Although review of literature for management of PHVT reveals no set guidelines, thrombolytic therapy, thrombectomy or prosthetic valve replacement are the currently available options. Previous studies of therapies for PHVT have lacked uniformity in definitions of obstruction, treatment success, and diagnostic techniques. In the absence of randomized clinical trial data to guide therapeutic strategies for PHVT, current guidelines rely on limited data and expert opinion. This has led to a variety of recommendations with regard to the role of surgery and thrombolysis with no class I recommendations being given [2] [3] [4] . Surgery is recommended as first-line therapy by the European guidelines regardless of clinical status, whereas the Society of Heart Valve Disease has recommended Letters to the Editor 477 fibrinolysis as first-line therapy in all cases of PHVT in the absence of a contraindication [2, 5] . The American College of Chest Physicians guideline [4] recommends thrombolysis as first-line therapy for thrombi less than 0.8 cm 2 , and the American Heart Association and American College of Cardiology guidelines suggest thrombolysis only for stable patients with PHVT and incomplete obstruction [3] .
Recently, Ö zkan et al. [6] evaluated a strategy of transesophageal echocardiography (TEE)-guided fibrinolysis with rapid infusion of streptokinase (Group I) versus slow infusion of streptokinase (Group II) versus full-dose tPA (100 mg) (Group III) versus half-dose (50 mg) slow infusion of tPA (Group IV) versus low-dose (25 mg) slow infusion of tPA (Group V). The investigators reported successful thrombolysis in 83.2% of cases without a significant difference between thrombolytic protocols. However, analysis of complication rates by group showed a statistically lower combined complication rate in Group V (10.5%) compared with all other groups. This study has shown that low-dose (25 mg) intravenous slow (6 h) infusion tPA given in discrete, successive sessions guided by serial TEE can be achieved with a low risk of complications and a high rate of success even in patients within New York Heart Association class III or IV [6] . Although Sensoy et al. treated their patients with 50-mg tPA, Ö zkan et al. showed that patients treated with 25-mg tPA had similar success (81.5 vs. 85.5%, respectively; P ¼ 0.46) but lower complication rates (29.6 vs. 10.5%, respectively; P ¼ 0.01) than the patients treated with 50-mg tPA. These results showed that a lower dose (25 vs. 50 or 100-mg tPA) and a slower infusion rate (6-h versus 90 min in former studies) were superior to the traditional thrombolytic treatment protocols, and had 0% mortality. Recent studies also suggest that further prolongation of the tPA regimen with low-dose (25 mg) and ultraslow (25 h) infusion could be associated with lower complication rates [7] . In conclusion, until prospective, randomized trials are published, the data from the current studies suggest that lower-dose, TEE-guided repeated, slow administration of tPA may be the best choice for efficacy and safety.
